Background On a global scale, type II diabetes mellitus (T2DM) remain a major health problem and it is the driver for chronic kidney disease (CKD). Despite this association, we still do not have sufficient biomarkers to anticipate better outcomes. Nglycosylation profiles are robust biomarkers and can be used for early monitoring of the progression of T2DM towards CKD. Methods In this cross-sectional study, we recruited 241 T2DM patients from January to May 2016. Demographic and anthropometric data were collected, following which fasting blood samples were collected for clinical analyses. Renal function decline was determined by estimation of glomerular filtration rate (eGFR) and N-glycosylation profiles were analysed by Ultraperformance liquid chromatography (UPLC). Results The prevalence of undiagnosed CKD was 31.53%. Compared to men, women had a statistically significantly higher HbA1c (p = 0.031), TG (p = 0.015), HDL-c (p < 0.0001), creatinine (<0.0001), urea (p < 0.028) and uric acid (p < 0.0001). T2DM patients with undiagnosed CKD had higher serum creatinine (145.75 ± 50.83 vs 88.59 ± 19.46, p < 0.0001), higher uric acid (361.10 ± 115.37 vs 294.54 ± 97.75; p < 0.0001) and higher urea (5.17 ± 2.35 vs 3.58 ± 1.19; p < 0.0001). After performing logistic regression and adjusting for age, sex and BMI, three N-glycan peaks [OR (95%CI): (GP12 (0.05(0.01-0.54), p = 0.013)); GP16 (0.61(0.43-0.87), p = 0.006)); GP22 (0.60(0.39-0.92), p = 0.018)) were associated with renal function. Conclusion There was an increased prevalence of undiagnosed CKD among T2DM patients. This prevalence is the consequence of uncontrolled modifiable risk factors, which collectively may lead to end stage renal disease (ESRD). Although, the identified N-glycans could not adequately predict incident CKD, our investigation indicates the potential role of N-glycosylation in renal function and that their inclusion may improve risk stratification for CKD.
Introduction
Chronic kidney disease (CKD) is a life-threatening condition responsible for many morbidities and mortalities worldwide [1] [2] [3] [4] . According to a systematic analysis on the global burden of diseases, it is the 18th cause of premature deaths [5] . However, apart from premature deaths being the worst outcome, those who survive it are prone to lifelong consequences including frequent hospitalisation [6, 7] , cognitive impairment [8] , poor quality of life [9] and overwhelming healthcare costs [7] .
CKD is established based on kidney damage or decline in function over a 3-month period [10] . For many years, both the National Institute for Health Excellence (NICE) [11] and the Kidney Outcomes Quality Initiative (KDOQI) [12] have recognised the estimates of glomerular filtration rate (eGFR) Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40200-018-0365-3) contains supplementary material, which is available to authorized users.
as a proxy measure of kidney function. Usually, eGFR estimates are evaluated using different equations or formulae such as the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) [13] , Modification of Diet in Renal Disease (MDRD) [14] , Cockcroft-Gault [15] and cystatin based formula [16] . Based on the eGFR estimates derived from these equations, CKD is classified as follows: Stage [1, 10, 17] . These evaluations have thus far, enabled disease labelling, risk stratification, intervention, drug dosing and prognostication [18] .
The main risk factors for CKD are proteinuria [19] , glomerulonephritis [20] , nephrolithiasis [21] , hypertension [22] and type II diabetes (T2DM) but amongst them, T2DM has been suggested to be the main driver of CKD [18] . Indeed, the projected trajectory is nearly half of all patients with T2DM may suffer from kidney dysfunction at some stage in their life [23] . This is because T2DM leads to oxidative stress and chronic inflammation that in turn fuels many abnormalities including endothelial dysfunction, mesangial-cell contraction, glomerular fibrosis and mesangial expansion. When untreated, these complications then advance into end-stage renal disease (ESRD) [18, 24, 25] . At ESRD, patients can only survive under kidney replacement therapy (i.e. dialysis or kidney transplantation).
Ghana, like many other countries in sub-Saharan Africa (SSA) and worldwide, has large numbers of people with T2DM and if the current trend persists, it will not be surprising to realise an explosion of T2DM and its associated CKD complications in the future [26, 27] . Early recognition of risk factors will promote better treatment and improve survival [26, 27] . However, CKD awareness among T2DM sufferers is generally low in this region [28] . In part, this can be attributed to limited health care resources which in turn, has slowed the commitment to research, health screening and surveillance. In fact, only a few studies have reported the prevalence of CKD in Ghana [28, 29] , and these studies were restricted to only some risk factors and failed to adequately explore other potential risk factors. Moreover, several studies have indicated the role of genetic and environmental factors to the pathophysiology of CKD but the contribution of epigenetic factors or posttranslational modifications is scarcely documented.
N-glycosylation is a widely recognised process where complex oligonucleotides (glycans) are pinned to asparagine residues of proteins [30] . When bound to proteins, glycans affect their trafficking, turnover, and other physiochemical properties including solubility and stability [31] [32] [33] [34] . Glycans are stable in normal conditions but are aberrant in abnormal or environmental perturbations [35] . Thus, glyco-profiling is a unique approach to deciphering the complexities in both healthy and pathophysiological conditions. For example, Nglycans are defective in inflammatory diseases such as rheumatoid arthritis [36] andsystematic lupus erythematosus (SLE) [37] . However, the role of N-glycans in renal function remains scarce.
Therefore, in a hospital based clinical study, we have used the CDK-EPI equation in conjunction with multiple metabolic risk factors to determine CKD risk among T2DM patients in Ghana. In addition, this study profiles N-glycans in T2DM with or without CKD.
Study design and methods
This cross-sectional study was conducted from January 2016 to May 2016. Of the 260 T2DM participants recruited for the study, analyses were performed on 241 participants because of missing biochemical data. Recruitment for the study was based on a purposive sampling approach where T2DM patients who reported at the Diabetic Centre, Komfo Anokye Teaching Hospital (KATH) were invited to participate. KATH is a referral hospital with over 1200 beds with not less than 100 diabetic/hypertensive patients attending the hospital every week [38] .
Inclusion and exclusion criteria
This study was conducted in consultation with clinicians and qualified health professionals. T2DM was diagnosed by clinicians at KATH and it was established based on the international classification of disease (ICD-10-CM Diagnosis Code E11.9). Each patient was carefully examined and their medical records thoroughly reviewed. As a result, we excluded all those individuals who were suffering from cancer, arthritis, infectious diseases, cardiovascular disease, thyroid disorders, pituitary disorders and adrenal disorders. The study did not include pregnant and lactating mothers. Since T2DM is largely a disease of ageing, the study recruited only individuals who were 30 years and above. Furthermore, to limit potential confounding and the likelihood of recruiting participants with type 1 diabetes, we excluded participants on insulin injections.
Demographic and anthropometric examination
Previous and current history of disease, family history of T2DM and hypertension were collected. In addition, information on health status and history of smoking and alcohol consumption as well as current physical activity were also collected using a structured questionnaire. Weight (kg) and height (cm) were measured with a standard stadiometer (SECA, Hamburg, Germany). These data were used to determine the body mass index (BMI); calculated as BMI = weight (kg)/ [height (m)] 2 . Waist and hip circumference were measured in cm using a tape measure and waist-to-hip ratio (WHR) was calculated as WHR = waist (cm)/hip (cm).
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured using a standard sphygmomanometer (Omron HEM711DLX, UK).
Clinical data
After an overnight fast, blood samples were collected from each participant. Samples were collected into tubes containing ethylenediaminetetraacetic acid (EDTA) anticoagulant, gel separator and fluoride oxalate. Samples were centrifuged (Mendelssohn, USA) at 3000 g at 4°C for 10 mins (centrifuge Eppendorf 5702R, Germany) to separate the whole blood. Plasma glucose levels were measured using a glucose oxidase method (Roche Diagnostics, COBAS INTEGRA 400 Plus, USA). 
Ultra-performance liquid chromatography
Separation of fluorescently labelled N-glycans was achieved on a HILIC on an Acquity UPLC instrument (Waters, USA) which comprised of a sample manager, quaternary solvent manager and fluorescence (FLR) detector set with excitation wavelength of 250 nm and an emission wavelength of 428 nm. Using a Waters BEH Glycan chromatography column with dimensions 150 × 2.1 mm i.d. and 1.7 μm BEH particles, labelled N-glycans were then separated in the presence of 100 mM ammonium formate as solvent A (pH 4.4) and ACN as solvent B. A linear gradient of 30-47% solvent A at a flow rate of 0.56 ml/min was applied while separation temperature was maintained at 25°C and sample temperature at 10°C. Calibration of the system was done using external standards of hydrolysed and 2-AB labelled glucose oligomers following which the data was automatically processed and integrated. Automatically integrated chromatograms were manually corrected. With the same intervals of integration, the total plasma glycome was separated into 39 glycan peaks and the relative abundance of each N-glycan peak expressed as a percentage of the total integrated area. From these 39 directly measured N-glycan peaks, an additional 21 derived glycan traits were calculated. These are high branching (HB), low branching (LB), neutral or no sialylation (S0), monosialylated (S1), disialylated (S2), trisialylated (S3), tetrasialylated (S4), agalactosylated (G0), monogalactosylated 
Statistical analysis
All continuous data was recorded as mean ± standard deviation and percentages for categorical variables. Association between CKD and metabolic risk factors were performed using linear regression and multiple logistic regression models. Odds ratios (ORs) at 95% confidence intervals (95% CI) were recorded for logistic regression analysis. Normalisation and batch correction on the UPLC data were performed in order to control for non-biological variability. Normality distribution of data was checked by the Kolmogov Smirnoff test as well as visualisation of QQ plots. However, because of the skewed nature of N-glycan data, interquartile ranges (IQRs) were used to describe the data. Depending on the normality distribution, between groups comparisons for continuous variables were performed using MannWhitney U-tests or Student-t tests and intergroup comparisons of categorical variables were performed using Chisquare tests. The Spearman correlation method was used to calculate the correlation coefficients (rho) between biochemical parameters and N-glycans. A p < 0.05 was considered statistically significant.
Results
All participants were physically examined, and their biochemical and clinical data collected. The mean ages of participants were 58.95 ± 10.98 years and 57.04 ± 10.77 years for men and women, respectively. There was female dominance in this study and the ratio of males to females was 99/142. This ratio was not surprising since the registered data from KATH shows that there are more women with T2DM than men. Also, compared to men, women were more willing and consented to participate in the study. Albeit, the age ranges for men and women were similar. After stratifying by gender, women were generally obese compared to men when BMI (23.9% vs. 10.4%; p = 0.001) was used as an obesity index. A higher proportion of men compared to women had a history of smoking (28.3% vs. 3.5%; p < 0.001) and alcohol consumption (58.6% vs. 31.7%; p < 0.0001). There was a significantly higher HbA1c (p = 0.031), TC (p = 0.015), HDL-c (p < 0.0001), creatinine (<0.0001), urea (p < 0.028) and uric acid levels (p < 0.0001) among women compared to men. Levels of SBP, DBP, FPG, TG, VLDL-c, eGFR and coronary risk ratio among females were not significantly different between males and females (p > 0.05). Generally, men engaged in more moderate physical activity compared to women (p < 0.035) ( Table 1) .
CKD was more prevalent in females than males. Age (p < 0.0001), education (p = 0.023), occupation (p < 0.035) and physical activity (p = 0.038) were significantly associated with CKD. Meanwhile (Table 3) .
In the bivariate analysis, there was a significant negative relationship between urea (β = −2.62; p < 0.0001) and uric acid (β = −0.02; p = 0.0161) with CKD. The r 2 indicated that the cause of CKD was influenced by 30.6% of urea and 4.2% of uric acid. Inverse and non-significant relationships were observed between CKD and age, SBP, FPG, TC, TG, HDLc, non-HDL-c, LDL-c, coronary risk ratio, and VLDL-c (Table 4) .
In the bivariate analysis, it was shown that urea and uric acids were independently associated with CKD. After including uric acid, TC, SBP, DBP, Urea, FPG, BMI, TG, age, HDLc, HbA1c, coronary risk, VLDL-c and LDL-c in the multivariate linear regression model, they influenced CKD by 55.7% (r 2 = 0.557). When the significant predictors, urea and uric acid were included in the model, CKD was influenced by 37.21% (r 2 = 0.3721). The predictive equation for this model was CKD =72.07-3.08*Urea-7.30*Uric acid (Table 5) .
Differential plasma N-glycan patterns in T2DM with CKD and those without CKD
The IQRsof all measured N-glycans are shown in Table 6 and there were distinct levels of N-glycans between T2DM with CKD and those without it. Generally, GP10 (FA2G2), GP16 (FA2G2S[6]1) and GP22 (FA2G2S [3, 6] 2) were higher among in T2DM without CKD compared to T2DM with CKD. In contrast, GP14 (A2G2S [6] 1, T2DM with CKD than those without it (p < 0.05). However, in Supplementary Table 2 , there were no statistical significance differences between N-glycan traits in T2DM + CKD and those without CKD.
A f t e r p e r f o r m i n g l o g i s t i c r e g r e s s i o n , G P 6 (FA2 [6] Data is expressed as mean ± standard deviation or (n %). Statistically significant differences (p < 0.05) are bold (FA2G2S [3, 6] 2) were significant in the crude (unadjusted) models (p < 0.05) ( Table 7) . However, after adjusting for Age, gender and BMI, only GP 12, GP16 and GP 22 were significant. There were no significant associations in the derived traits after performing logistic regression (Supplementary Table 3 ). . This prevalence rate is comparable to a previous study conducted among 280 T2DM patients in an urban community in Ghana [28] with the difference being 1.53%. As the determination of prevalence of CKD is based on the CKD-EPI Creatinine Equation in both studies, the slight increase in CKD in our study can be attributed to the proportion of the aged population in our study and the likelihood that these aged individuals may have been suffering from other clinical conditions (e.g. nephrosclerosis and undiagnosed ischaemic kidney disease) which we could not diagnose at the time of our investigation. Surprisingly, compared with T2DM patients without CKD, those with CKD in our present study had lower HbA1c levels (Table 2) , however, the clinical implications of this is negligible, given the difference was only 0.57% and a p value of 0.049. Besides, as shown in Table 2 , the levels of FPG in T2DM with CKD and T2DM without CKD were not statistically significantly different. Other plausible explanation is the fewer number of T2DM participants with CKD compared to those without it. The use of BMI as an obesity index has been criticised, hence the association between BMI and CKD has been conflicting in many studies. For example, whereas one study showed that the risk of developing advanced kidney malfunction is threefold higher in patients with BMI > 30, another study showed that the association between BMI and kidney dysfunction was insignificant [41, 42] . The present study agrees with the latter in that BMI was not an independent risk factor for CKD. Perhaps, complementing BMI with other fat indicators or measurements such as visceral fat and fat mass index (FMI) would have yielded a better association.
Consistent with other studies [43, 44] , our findings show that T2DM patients with high systolic BP had increased odds for CKD (Table 3) . Although it remains controversial whether elevated blood pressure is the cause or the consequence of kidney dysfunction, it has been suggested that elevated blood pressure promotes arterial stiffening and intimal thickening in the kidney parenchyma and subsequently results in glomerulosclerosis [45, 46] . Similarly, T2DM patients with high TG levels had increased odds for developing CKD. This confirms the findings by other studies [41, 47] . Although the exact mechanism is not fully understood, it has been suggested that the correlation between high TG and CKD is related to regulation of lipoprotein lipase activity during TG catabolism. This enzyme is regulated by two proteins: apolipoprotein C-II and apolipoprotein C-III that act antagonistically. That is, whilst apolipoprotein C-II activates lipoprotein lipase, apolipoprotein C-III inhibits it. During CKD, there is an increase in apolipoprotein C-III (i.e. decrease apolipoprotein C-II/C-III ratio) and this results in lipase inactivation and subsequent TG accumulation [48] [49] [50] .
Thus far, we have used routine biochemical markers to establish the presence of CKD amongst T2DM, however, it is worth investigating the potential role of post-translational modification in kidney function. From the results, it was evident that N-glycosylation was associated with age and gender as previously reported [51] [52] [53] [54] [55] [56] [57] [58] [59] and this is attributable to hormonal differences (Fig. 1) . The results of this present study showed that core fucosylated N-glycans without bisection [GP 10 (FA2G2), GP 16 (FA2G2S[6]1) and GP22 (FA2G2S [3, 6] 2) was significantly higher in T2DM patients with normal renal function (Table 6 ). Our findings agree with that of Barrios et al. [59] who showed that core fucosylated glycans that lack bisecting GlcNAc was associated with decreased risk of CKD. Core fucosylated N-glycan is an important molecule in notch signalling, growth factor receptor expression and adhesion molecule activity. Moreover, bisecting N-acetyl glucosamine on IgG facilitates antibody dependent cellular cytotoxicity (ADCC) or a proinflammatory state since the presence of bisecting N-acetyl glucosamine on N-glycans inhibits core fucosylation and indirectly promotes the binding of IgG molecules to Fcγ receptor III [54, 58] . Further, after performing a logistic regression and adjusting for covariates, CKD was associated with an increased levels of complex N-glycans (GP12, GP16 and GP22) ( Table 7) . These identified N-glycans have crucial role i n k i d n e y f u n c t i o n . F o r e x a m p l e , G P 1 2 , a Data presented as median interquartile range (IQR). W-Wilcoxon statistic, Tests of significance were two tailed (*p < 0.05) and are bold monogalactosylated, monosialylated biantennary N-glycan with bisecting GlcNAc, has previously been associated with increased HbA1c levels among CKD patients with type I diabetes mellitus (T1DM). Also, GP16 has been associated with albumin-to-creatinine ratio and eGFR slope in T1DM [55] . Plausible explanation in the context of renal function are that increased plasma glycemia triggers the flux of glucose in the hexosamine pathway. In turn, this leads to the production of uridine-diphosphate N-acetylgucosamine, which acts as a substrate in N-glycosylation and increase the production of complex N-glycans. In parallel, this events indirectly upregulate epidermal growth receptor; a molecule which as [54, 55] . Further, since the identified N-glycans (GP12 and GP16) have been implicated in renal function in both T1DM and T2DM, this result suggests a possible mechanistic similarit y between the two main types of diabetes. However, further investigation is warranted to gain additional insights.
A previous study has shown that IgG galactosylation is associated with complement activation and renal damage [56] and that decreased IgG galactosylation is linked with CKD. On the contrary, the present study showed that galactosylated N-glycan GP14 (A2G2S[6]1), was higher in T2DM patients with CKD compared to those without it. Also, after performing logistic regression in the crude model, agalactosylated N-glycans GP7 (M6D1-D2), core fucosylated monogalactosylated N-glycans GP6 (FA2[6]BG1) and digalactosylated N-glycans (GP14) were found to be associated with increased risk of CKD. These discrepancies may be attributed to the glycoprotein under investigation. In this study, total N-glycome was measured, exploring the whole plasma proteins whereas the previous study focused on IgG N-glycan. Exploring total plasma N-glycome is more beneficial as it reflects N-glycosylation and the relative abundance of proteins in circulation.
The present study has revealed the independent association between elevated uric acid, urea and creatinine and renal dysfunction as previously reported [60] [61] [62] [63] [64] [65] (Tables 4  and 5 ). Subsequently, we sought to investigate how Nglycans correlate with these renal function markers. Some important highlights were that trigalactosylated [(GP26, GP30, GP31, GP32) and tetragalactosylated structures (GP 34 and GP36) were negatively correlated with creatinine whereas core fucosylated (GP4, GP5, GP20) and trigalactosylated N-glycans (GP30) significantly correlated with uric acid amongst T2DM patients with CKD ( Fig. 2 and Supplementary Tables 4 & 5) . However, these analyses does not adequately distinguish or adequately predict incident CKD. This can be blamed on the fewer number of T2DM patients with CKD and the impact of antidiabetic medications. A recent study has shown that the majority of the participants utilised different medications including
GP11
GP18 GP22 GP17 GP12 GP34 Percentage of N-glycan group Fig. 1 Loiss plots of the relationship between N-glycans and Age among cases. Blue and red curves are fitted linear regression models. The shaded region is the 95% confidence intervals on the fitted values diuretics, statins, glucocorticoids and anti-malarial agents [27] . These medications may influence serum uric acid levels and hence, the observed results could be overestimated.
The present study has limitations that need to be mentioned. First, metabolic risk factors such as blood pressure, blood glucose, lipid profiles and kidney dysfunction markers were limited to only one measurement whereas CKD presence should be established following multiple estimates for over 3 months. Again, because the study was a cross-sectional one, we were unable to determine the direction or the causal relationship between risk factors and CKD.
Outlook and perspectives
This study provides a stimulus for future research. Here, we have established the presence of CKD by estimating GFR with CKD-EPI equation. Apart from the aforementioned biomarkers, imaging techniques should be employed to establish the presence or absence of CKD. For example, ultrasonographic techniques can be used to examine the size and texture of the kidneys and determine possible abnormalities. In addition, spectral doppler and color doppler with ultrasonography as well as computer tomography, elastography and radiography are powerful tools for detecting CKD. Further, these efforts can be complemented with histopathological methods (e.g. renal biopsy) to confirm diagnosis [66] [67] [68] [69] .
Conclusion
The present study showed that undiagnosed CKD is prevalent among the T2DM patients. This was established based on the CKD-EPI equation. However, reporting incident CKD was not sufficient with this equation alone and a b
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Renal funcƟon markers
Renal funcƟon markers therefore we explored the N-glycosylation profiles of the participants. The study revealed specific complex Nglycans that were associated with fucosylated N-glycans. Future investigations may better reveal the role of the identified complex N-glycans and renal function.
